MDXHEALTH
MDXHNASDAQTrading Snapshot
- Day Range
- $0.18 – $0.20
- 52-Week Range
- $0.17 – $5.33
- Volume (shares)
- 4,250
- Avg Volume (shares)
- —
- Shares Outstanding
- 95.4M
- Next Earnings
- —
Fundamentals Snapshot
- Annual Revenue
- $108M
- Last Q Revenue
- $27M
- P/E Ratio
- —
- P/S Ratio
- 0.1x
- EPS (TTM)
- $-0.89
- Dividend Yield
- —
- Dilution (1yr)
- +2.4%
MDXHEALTH
MDXH
StockOtter · stockotter.spaceAbout MDXHEALTH
MDxHealth SA is a commercial-stage precision diagnostics firm delivering specialized urologic solutions across the globe. Its international footprint includes the United States, various European nations such as the Netherlands, Belgium, Spain, Poland, Italy, and the wider European Union. The company's innovative genomic testing portfolio for prostate cancer comprises SelectMDx, a non-invasive urine test, and ConfirmMDx, an epigenetic diagnostic tool. These advanced offerings enable medical professionals to precisely identify clinically significant prostate cancer, thereby minimizing reliance on invasive procedures and their associated risks. Established in 2003, with its headquarters in Herstal, Belgium, the entity was formerly known as OncoMethylome Sciences SA until its renaming to MDxHealth SA in October 2010.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Insufficient data for all five components.
Analyst Ratings
ⓘLatest News & Updates
News unavailable.